[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609449":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":42,"responsibleParty":156,"collaborators":158,"id":161,"slug":25,"hasResults":162,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":25,"eligibilityCriteria":166,"healthyVolunteers":162,"sex":167,"minAge":168,"maxAge":169,"enrollmentInfo":170,"targetDuration":25,"studyType":173,"phases":174,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":191},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ALN-5288","EXPERIMENTAL","Participants will be administered ALN-5288 in the Double-blind (DB) Period and Open-Label Extension (OLE) Period.",[13],"Drug: ALN-5288",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo + ALN-5288","PLACEBO_COMPARATOR","Participants will be administered placebo in the DB Period and ALN-5288 in the OLE Period.",[13,19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","ALN-5288 will be administered IT.",[9,15],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo","Placebo will be administered IT.",[15],[31],{"name":32,"affiliation":5,"role":33},"Medical Director","STUDY_DIRECTOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":36,"role":37,"phone":41,"phoneExt":25,"email":39},"1-877-256-9526",[43,56,64,72,78,88,96,106,114,122,132,140,148],{"facility":44,"status":45,"city":46,"state":25,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":25},"Clinical Trial Site","RECRUITING","Montreal","H3G 1H9","Canada","CA",{"type":51,"coordinates":52},"Point",[53,54],-73.58781,45.50884,{"lat":54,"lon":53},{"facility":44,"status":45,"city":57,"state":25,"zip":58,"country":48,"countryCode":49,"cosmosGeoPoint":59,"geoPoint":63,"contacts":25},"Ottawa","K1Z 1G3",{"type":51,"coordinates":60},[61,62],-75.69812,45.41117,{"lat":62,"lon":61},{"facility":44,"status":45,"city":65,"state":25,"zip":66,"country":48,"countryCode":49,"cosmosGeoPoint":67,"geoPoint":71,"contacts":25},"Toronto","M3B 2S7",{"type":51,"coordinates":68},[69,70],-79.39864,43.70643,{"lat":70,"lon":69},{"facility":44,"status":73,"city":65,"state":25,"zip":74,"country":48,"countryCode":49,"cosmosGeoPoint":75,"geoPoint":77,"contacts":25},"NOT_YET_RECRUITING","M5T 2S8",{"type":51,"coordinates":76},[69,70],{"lat":70,"lon":69},{"facility":44,"status":73,"city":79,"state":25,"zip":80,"country":81,"countryCode":82,"cosmosGeoPoint":83,"geoPoint":87,"contacts":25},"'s-Hertogenbosch","5223","Netherlands","NL",{"type":51,"coordinates":84},[85,86],5.30417,51.69917,{"lat":86,"lon":85},{"facility":44,"status":73,"city":89,"state":25,"zip":90,"country":81,"countryCode":82,"cosmosGeoPoint":91,"geoPoint":95,"contacts":25},"Amsterdam","1081 GN",{"type":51,"coordinates":92},[93,94],4.88969,52.37403,{"lat":94,"lon":93},{"facility":44,"status":73,"city":97,"state":25,"zip":98,"country":99,"countryCode":100,"cosmosGeoPoint":101,"geoPoint":105,"contacts":25},"Barcelona","08036","Spain","ES",{"type":51,"coordinates":102},[103,104],2.15899,41.38879,{"lat":104,"lon":103},{"facility":44,"status":45,"city":107,"state":25,"zip":108,"country":99,"countryCode":100,"cosmosGeoPoint":109,"geoPoint":113,"contacts":25},"Madrid","28040",{"type":51,"coordinates":110},[111,112],-3.70256,40.4165,{"lat":112,"lon":111},{"facility":44,"status":73,"city":115,"state":25,"zip":116,"country":99,"countryCode":100,"cosmosGeoPoint":117,"geoPoint":121,"contacts":25},"Sant Cugat del Vallès","08190",{"type":51,"coordinates":118},[119,120],2.08611,41.47063,{"lat":120,"lon":119},{"facility":44,"status":45,"city":123,"state":25,"zip":124,"country":125,"countryCode":126,"cosmosGeoPoint":127,"geoPoint":131,"contacts":25},"Glasgow","G51 4TF","United Kingdom","UK",{"type":51,"coordinates":128},[129,130],-4.25763,55.86515,{"lat":130,"lon":129},{"facility":44,"status":45,"city":133,"state":25,"zip":134,"country":125,"countryCode":126,"cosmosGeoPoint":135,"geoPoint":139,"contacts":25},"London","WC1N 3BG",{"type":51,"coordinates":136},[137,138],-0.12574,51.50853,{"lat":138,"lon":137},{"facility":44,"status":73,"city":141,"state":25,"zip":142,"country":125,"countryCode":126,"cosmosGeoPoint":143,"geoPoint":147,"contacts":25},"Sheffield","S10 2JF",{"type":51,"coordinates":144},[145,146],-1.4659,53.38297,{"lat":146,"lon":145},{"facility":44,"status":45,"city":149,"state":25,"zip":150,"country":125,"countryCode":126,"cosmosGeoPoint":151,"geoPoint":155,"contacts":25},"Southampton","SO16 6YD",{"type":51,"coordinates":152},[153,154],-1.40428,50.90395,{"lat":154,"lon":153},{"type":157,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[159],{"name":160,"class":6},"Regeneron Pharmaceuticals","100609449",false,"NCT07214727","A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease","A Phase 1, Randomized, Placebo-controlled Study With a Double Blind Period With Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients With Alzheimer's Disease","Inclusion Criteria:\n\n* Is able and willing to meet all study requirements in the opinion of the Investigator\n* Has a diagnosis of Alzheimer's disease (AD) based on clinical findings supported by cerebrospinal fluid (CSF) biomarkers or positive positron emission tomography (PET) amyloid imaging within 7 years prior to screening\n* Has mild cognitive impairment (MCI) or dementia due to AD\n\nExclusion Criteria:\n\n* Has non-AD dementia\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>2× upper limit of normal (ULN)\n* Has total bilirubin \\>1.5×ULN\n* Has known human immunodeficiency virus infection\n* Has history of hepatitis C virus or current hepatitis B virus infection\n* Has systolic blood pressure \\>160 mmHg and\u002For a diastolic blood pressure \\>100 mmHg after 10 minutes of rest at screening\n* Has an estimated glomerular filtration (eGFR) of \\\u003C45 mL\u002Fmin\u002F1.73 m\\^2 at screening\n* Has clinically significant ECG abnormalities at screening\n* Has uncontrolled psychiatric disease, including patients deemed by the Investigator to be at significant risk of suicide, major depressive episode, psychosis, confusional state, or violent behavior\n* Has history of bleeding diathesis or coagulopathy due to chronic conditions\n* Has a medical history of brain or spinal disease that would interfere with the IT injection and LP procedures\n* Has history of uncontrolled seizures within the last 6 months prior to Screening","ALL","40 Years","80 Years",{"count":171,"type":172},50,"ESTIMATED","INTERVENTIONAL",[175],"PHASE1","The purpose of this study is to:\n\n* Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD)\n* Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration",[178],"Alzheimer's Disease",[180,181],"AD","Dementia","2026-06-10",{"date":184,"type":185},"2026-06-12","ACTUAL",{"date":187,"type":185},"2025-10-15",{"date":189,"type":172},"2030-03-06",{"name":5,"class":6},13]